Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 28;12(8):2091. doi: 10.3390/cancers12082091

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

PRMT5 inhibitor treatment is shown to result in a significant G₂ phase cell cycle arrest in the KRAS mutant CRC cells by cell cycle analysis. (a) Flow cytometry dot plots displaying cell cycle assay results; (b) Quantified cell cycle assay results displaying that PRMT5 inhibitor treatment showed an 8.6% (p < 0.005) greater increase in G₂ phase cells, as well as 6.2% (p < 0.05) and 2.3% (p < 0.05) greater decreases in G₁ and S phase cells respectively after 60 h of 10 µM PRMT5 inhibitor treatment in the KRAS mutant CRC cells when compared to the KRAS WT CRC cells. Data are expressed as means + SD from four independent experiments using four CRC cell lines (2 KRAS mutant, 2 KRAS WT). Data for the individual cell lines can be seen in Figures S2 and S3. * represents p < 0.05.

PRMT5 inhibitor treatment is shown to result in a significant G₂ phase cell cycle arrest in the KRAS mutant CRC cells by cell cycle analysis. (a) Flow cytometry dot plots displaying cell cycle assay results; (b) Quantified cell cycle assay results displaying that PRMT5 inhibitor treatment showed an 8.6% (p < 0.005) greater increase in G₂ phase cells, as well as 6.2% (p < 0.05) and 2.3% (p < 0.05) greater decreases in G₁ and S phase cells respectively after 60 h of 10 µM PRMT5 inhibitor treatment in the KRAS mutant CRC cells when compared to the KRAS WT CRC cells. Data are expressed as means + SD from four independent experiments using four CRC cell lines (2 KRAS mutant, 2 KRAS WT). Data for the individual cell lines can be seen in Figures S2 and S3. * represents p < 0.05.